New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:10 EDTMYGNMyriad presents myPath Melanoma clinical validation study results
Myriad Genetics presented results from a pivotal clinical validation study of the Myriad myPath Melanoma test at the 2014 American Society of Clinical Oncology annual meeting. The Myriad myPath Melanoma test has now shown reproducible results in two large cohorts. Last November, Myriad presented results from its verification study at the American Society of Dermatopathology annual meeting. Data from that verification study of 464 lesions showed that the Myriad myPath Melanoma test had greater than a 90 percent diagnostic accuracy in differentiating malignant melanoma from benign skin lesions in a variety of subtypes. Additionally, an analysis of a prospective clinical utility study was highlighted at ASCO and initial findings from that study are consistent with earlier findings from a retrospective clinical utility study that was presented at the United States & Canadian Academy of Pathology's annual meeting in March. The USCAP data demonstrated a 33% change in medical management based upon the Myriad myPath Melanoma test result.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 11, 2015
14:20 EDTMYGNWilliam Blair diagnostic services analyst holds analyst/industry conference call
Analysts, along with Dr. Todd Cohen, provide an industry update on an Analyst/Industry conference call to be held on April 16 at 3 pm.
April 8, 2015
08:45 EDTMYGNLife Sciences group well positioned heading into Q1 earnings, says Cowen
Cowen said the Life Sciences sector looks well positioned heading into Q1 earnings despite the group outperforming the broader market recently. The firm believes headwinds have intensified and multiples have stretched, but they see the downside risk as limited with upside risk dependent on improving end-market commentary, new products and milestones, and new details on capital deployment. Stocks in the space include Affymetrix (AFFX), Fluidigm (FLDM), GenMark (GNMK), Myriad Genetics (MYGN) and Quidel (QDEL).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use